M Axel Wollmer, Insa Neumann, Stefanie Jung, Agnès Bechinie, Julian Herrmann, Antje Müller, Peter Wohlmuth, Larissa Fournier-Kaiser, Christian Sperling, Liza Peters, Jonas Kneer, Jannis Engel, Frank Jürgensen, Jara Schulze, Matthias Nagel, Welf Prager, Christopher Sinke, Kai G Kahl, Matthias Karst, Birger Dulz, Tillmann H C Kruger
BACKGROUND: Inhibition of frowning via injections of botulinum toxin A (BTX) into the glabellar region has shown beneficial effects in the treatment of major depression. Preliminary research suggests that improvements in the affective domain are not depression-specific, but may also translate to other psychiatric disorders. AIM: This 16-week, single-blind, two-center randomized controlled trial investigated the influence of BTX on clinical symptoms of borderline personality disorder (BPD)...
February 2022: Journal of Psychopharmacology